Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Gross ProfitIncome from Continuing OperationsIncome towards Parent CompanyInterest & Investment IncomeNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares OutstandingShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Janux Therapeutics (JANX) Income from Continuing Operations: 2020-2024

Historic Income from Continuing Operations for Janux Therapeutics (JANX) over the last 5 years, with Dec 2024 value amounting to -$69.0 million.

  • Janux Therapeutics' Income from Continuing Operations rose 13.35% to -$24.3 million in Q3 2025 from the same period last year, while for Sep 2025 it was -$101.9 million, marking a year-over-year decrease of 68.32%. This contributed to the annual value of -$69.0 million for FY2024, which is 18.36% down from last year.
  • According to the latest figures from FY2024, Janux Therapeutics' Income from Continuing Operations is -$69.0 million, which was down 18.36% from -$58.3 million recorded in FY2023.
  • Janux Therapeutics' Income from Continuing Operations' 5-year high stood at -$5.0 million during FY2020, with a 5-year trough of -$69.0 million in FY2024.
  • In the last 3 years, Janux Therapeutics' Income from Continuing Operations had a median value of -$63.1 million in 2022 and averaged -$63.4 million.
  • Its Income from Continuing Operations has fluctuated over the past 5 years, first slumped by 547.10% in 2021, then climbed by 7.56% in 2023.
  • Janux Therapeutics' Income from Continuing Operations (Yearly) stood at -$5.0 million in 2020, then slumped by 547.10% to -$32.7 million in 2021, then plummeted by 93.01% to -$63.1 million in 2022, then climbed by 7.56% to -$58.3 million in 2023, then fell by 18.36% to -$69.0 million in 2024.